Abstract. Atrial fibrillation (AF) is the most common form of arrhythmia encountered in clinical practice, and contributes to cardiovascular morbidity and mortality. Despite significant advances in the understanding of the mechanisms associated with AF, the number of effective biomarkers and viable therapeutic targets remains relatively limited. In this study, 2-DE and MS/MS analysis was used to identify differentially expressed proteins in human atrial appendage tissues from patients with AF (n=4) compared to controls with sinus rhythm (SR; n=5). All subjects had rheumatic heart disease. Following 2-DE analysis, Coomassie Brilliant Blue staining and MS/MS identification, a total of 19 protein spots were found to be differentially expressed between the AF and SR groups. By cluster and metabolic/signaling pathway analysis, these proteins were divided into three major groups: proteins involved in the cytoskeleton and myofilament, energy metabolism associated proteins, and proteins associated with oxidative stress. The proteins identified in this study may enable a better understanding of the molecular mechanisms of AF, and may provide useful biomarkers and novel targets for drug development.
Introduction
Atrial fibrillation (AF) is the most common form of arrhythmia encountered in clinical practice, and contributes to cardiovascular morbidity and mortality (1, 2) . The prevalence of AF has been shown to increase with age: in individuals 55-59 years of age, it has a prevalence of 0.7, while in individuals 85 years of age or older, the prevalence increases to 17.8% (3, 4) . Consequently, though the number of patients with AF in the US was 2.3 million in 2001 (5) , it has been estimated that this will reach 15.9 million by 2050 (6) .
Effective therapy and prevention is crucial for the control of AF-related morbidity and mortality. However, the availability of effective biomarkers and viable therapeutic targets remains limited, despite recent significant advances in the understanding of the mechanisms associated with AF. Therefore, new methods leading to further insights into the underlying mechanisms of AF are required to identify effective biomarkers and novel therapeutic targets.
In recent years, proteomics has been used to identify diagnostic biomarkers for the early detection of cardiovascular disease, as well as novel therapeutic targets for its treatment (7) . Using the proteomics method, the molecular mechanisms that contribute to AF were examined in several animal models of pacing-induced AF (8, 9 ). More recently, three different groups carried out a proteomic analysis of atrial fibrillation using human atrial appendage tissues (10) (11) (12) . Combining metabolomic and proteomic analysis of human atrial fibrillation, Mayr et al (10) showed that the disrupted regulation of energy metabolites preceded the onset of postoperative AF. Modrego et al (11) performed a proteomic analysis to compare the expression of proteins between left atrial appendages (LAA) and right atrial appendages (RAA) obtained from patients with mitral valve disease with either sinus rhythm or permanent atrial fibrillation. Moreover, García et al (12) found that the down-regulation of the structural protein fibulin-1
Comparative proteomic analysis of atrial appendages from rheumatic heart disease patients with sinus rhythm and atrial fibrillation in atrial tissue from AF patients may reflect the myocardial structural changes that take place in patients with arrhythmia. These proteomic analyses of human atrial fibrillation have contributed to the understanding of the mechanisms leading to atrial fibrillation. However, all three studies investigated European populations; AF in Asian populations has yet to be investigated. Since the incidence of AF is related to race (5) and differs between developed and developing countries, we performed a proteomic analysis in a Chinese population to identify differentially expressed proteins in the human atrial appendage tissues of patients with AF (n=4) compared to controls with sinus rhythm (SR; n=5). All the subjects had with rheumatic heart disease, which is a significant cause of AF.
Patients and methods
Patients. The study comprised 9 subjects, all diagnosed with rheumatic heart disease (RHD). Four of the patients had previously been diagnosed with AF, while the other 5 had SR and served as controls. The clinical characteristics of the patients are summarized in 
2-Dimensional gel electrophoresis (2-DE) and image analysis.
2-DE was was conducted as previously described (13) with minor modifications. Briefly, right atrial appendages were homogenized and sonicated in lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 100 mM DTT, 0.2% ampholyte pH 3-10; Bio-Rad, USA) containing protease inhibitor cocktail. IPG strips (17 cm, pH 7-10, non-linear; Bio-Rad) were passively rehydrated (2 mg protein loading amount) for 12-16 h. Four replicates of each sample were run. Statistical analysis was performed by applying the student's t-test. Spots that showed consistent and significant differences (>2-fold, p<0.05) were selected for mass spectrometry (MS) analysis.
In-gel digestion, MS/MS analysis and protein identification.
In-gel digestion of protein spots was performed using MS-grade Trypsin Gold (Promega, Madison, WI) according to the manufacturer's instructions. ESI-Q-TOF MS/MS analysis and protein identification were performed as described previously (14) with minor modifications. Briefly, mass spectra were acquired using a Q-TOF mass spectrometer (Micromass, Manchester, UK) coupled with an ESI ion source (Micromass). For MASCOT analysis, peptide and fragment mass tolerance were set at 0.1 and 0.2 Da respectively.
Results

Patient characteristics.
There were no significant differences in terms of age or New York Heart Association (NYHA) classifications between the SR and AF groups. Moreover, pre-operative Color Doppler echocardiography showed no differences in RVOT, LVDd, LVDs, IVS and LVPW, with the exception of LAD (Table Ⅰ) , in line with a recent report that the left atrial size was significantly greater in patients with AF than in those with SR (11).
2-DE profiling of differentially expressed proteins between SR and AF patients.
To examine changes in protein expression in patients with AF, the proteome of atrial appendages was compared between patients with SR and those with AF using 2-DE with a broad pH gradient (pH 3-10 non-linear).
To avoid misidentifications due to gel-to-gel variations, only protein features that were present in at least 75% of the gels belonging to a given group (SR or AF) were considered in the analysis. A pair of representative 2-DE maps is shown in Fig. 1 . After automatic spot detection, background subtraction and volume normalization, 802±47 protein spots in the SR and 813±38 protein spots in AF groups were detected. As a result, 30 protein spots exhibited >2-fold changes (p<0.05), 19 of which were successfully identified by MS (Fig. 1) . Thirteen of the proteins identified were up-regulated in the AF gels, whereas 6 were up-regulated in the SR samples. All the detected proteins showed a difference of not more than ~10 kDa compared to the theoretical values calculated on the basis of the ORFs in the genome.
Identification of differentially expressed proteins.
Of the 30 spots selected, proteins in 19 spots were positively identified ( Table Ⅱ) . The average value of the MOWSE scores was 209, while the number of unique peptides identified by MS/ MS was 5. A representative MS map of spot #3 is shown in Fig. 2A . A MS/MS map of the parent ions (m/z 814.9725) is shown in Fig. 2B , indicating that this peptide sequence is ITSAYLQDIENAYK, part of the sequence of the protein NADH dehydrogenase [ubiquinone] 1 α subcomplex subunit 10, mitochondrial (NDUAA). As shown in Fig. 2C and D, the output of the database search by MASCOT resulted in the identification of NDUAA.
Functional classification. Functional classification of the identified proteins was performed using the Gene Ontology annotation system. A total of 19 proteins were revealed to be differentially expressed between the AF and SR groups. These proteins have functions in diverse biological processes, including energy metabolism, apoptosis and oxidative stress ( Table Ⅲ) . Using cluster analysis (by Cluster 3.0 and Treeview), the proteins identified were divided into three major groups: cytoskeleton and myofilement associated proteins, proteins involved in energy metabolism and proteins associated with oxidative stress (Table Ⅲ) .
Discussion
AF the most common arrhythmia in clinical practice and results in cardiovascular morbidity and mortality. However, despite significant advances in our understanding of the mechanisms associated with AF, no effective biomarkers or viable therapeutic targets have been identified. In the present study, 2-DE-based proteomic analysis of human atrial tissue was carried out to identify novel biomarkers for diagnosis and new targets for therapy. Differentially expressed proteins in tissues from patients with AF versus matched controls with SR were compared, and 19 proteins were found to be differentially regulated between the groups. These can be divided into three major groups: proteins involved in cytoskeleton and myofilament, energy metabolism associated proteins, and proteins associated with oxidative stress.
Cytoskeleton and myofilament. In AF patients, myosin light chain 3 (MLC3) and cardiac troponin I (cTnI) were up-regulated compared to the SR group. These play a critical role in regulating cardiac morphogenesis and construction. It is worth noting that, as members of the cardiac sarcomere proteins, mutations of these two genes have been associated with hyper- trophic cardiomyopathy (HCM) (15) (16) (17) , while HCM patients have a greater likelihood of developing atrial fibrillation (18) , which is also the most common arrhythmia observed in HCM (19) . Combined with our results, these findings suggest that the mutation or deregulation of MLC3 and cTnI may be involved in the initiation and development of AF. Indeed, the downregulation of cTnI in the myocardium of patients with AF has been reported (20, 21) , and this down-regulation has been found to be partly due to protein degradation by calpain (22) . This seems to be in conflict with our present results. However, Thijssen et al (23) proposed that the expression of cTnI was closely related to the stage of AF, i.e., cTnI expression was up-regulated in chronic AF compared to earlier-stage AF, in part due to the suppression of degradation. Both types of keratin, type II cytoskeletal 1 (K2C1) and type I cytoskeletal 9 (K1C9) keratin, are crucial structural constituents of the cytoskeleton. Notably, the expression of K2C1 in the heart is the second highest in humans, as shown by the EST profile from Unigene. Although K2C1 was downregulated and K1C9 was markedly up-regulated in AF with respect to SR patients, there have been no reports regarding the relationship between these two proteins and AF. Further studies are required to clarify the relationship between keratins and AF.
Energy metabolism. The maintenance of the normal function of the ion channels, such as calcium, sodium and potassium channel proteins, is critical for electric stability, which depends on sufficient energy supply. It has been shown that energy metabolism and arrhythmia are interdependent: the deregulated cellular energetic state predisposes patients to atrial arrhythmias, while atrial rhythm disturbances also influence metabolic activity (24) . In this study, seven proteins involved in energy metabolism were differentialy expressed in human atrial tissues from AF and SR patients. These play essential roles in processes including fat acid β-oxidation, glycolysis, electron transport and the tricarboxylic acid cycle (TAC). Here, we mainly examined the identified proteins associated with fat acid β-oxidation and glycolysis.
Fat acid β-oxidation. Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADV) and δ(3,5)-δ(2,4)-dienoyl-CoA isomerase, mitochondria l (ECH1) all function in the fat acid β-oxidation pathway, which produces the main energy substrate-acetyl-CoA (25) . ECH1 expression was down-regulated in AF, while ACADV was up-regulated. However, considering that, as opposed to the auxiliary effect of ECH1, ACADV catalyzes the initiated step of mitochondrial β-oxidation of straight-chain fatty acid, the fatty acid of β-oxidation appeared to be eventually enhanced in AF as a compensatory mechanism, since atrial fibrillation is a hypermetabolic state (26) .
Glycolysis. Expression levels of the pyruvate kinase isozymes M1/M2 (KPYM) and α-enolase (ENOA) were increased in samples from AF versus SR patients. Both catalyze the transfer of a phosphoryl group from phosphoenolpyruvate to ADP in the penultimate step of glycolysis, generating ATP and pyruvate. Increased expression of these two proteins may be a longer-term decreased energy saving adaptation in response to increased metabolic needs. Other enzymes involved in different energy metabolism pathways, such as electron transport and TAC, were differentially expressed in atrial appendages from AF and SR patients, which further suggests that there is a close relationship between energy metabolism and AF.
Oxidative stress. Accumulating evidence has demonstrated the involvement of oxidative stress in atrial tissue during AF, suggesting it plays a role in the remodeling phenomenon (27) (28) (29) . Furthermore, several pharmacological approaches with non-channel-blocking drugs with antioxidant and antiinflammatory properties have shown beneficial effects on AF development (30) (31) (32) (33) .
Peroxiredoxin-1 (PRDX1) and thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) are members of the peroxiredoxin family of antioxidant enzymes, and play an antioxidant protective role in cells. Within erythrocytes, PRDX1 protected hemoglobin from irreparable damage inflicted by reactive oxygen species, which otherwise leads to anemia (34, 35) . Additionally, it suppressed tyrosine kinase signaling, potentially regulating vascular remodeling (36). Combined with the up-regulation of PRDX1 in AF patients observed in this study, it is possible that PRDX1 protects the heart from oxidative damage during AF. PRDX3 confers protection against oxidative stress within the mitochondria of aortic cells and within the ischemic rat myocardium (37,38). The decrease in the expression of PRDX3 in our AF sample is in line with previous observations that PRDX3 is downregulated in the failing myocardium, at least in terms of mRNA expression (39) . Superoxide dismutase [Cu-Zn] (SOD3) is another antioxidant enzyme that catalyzes the dismutation of two superoxide radicals into hydrogen peroxide and oxygen, and is thought to protect the brain, lungs, heart and other tissues from oxidative stress. SOD3 deficiency has been found to exacerbate transverse aortic constriction-induced myocardial oxidative injury (40) . Overexpression of SOD3 protected against myocardial infarction-induced congestive heart failure (41) . We speculated that the increased expression of SOD3 observed in AF versus SR patients has a protective effect in patients with AF.
Study limitations.
In the present study, only a small number of patients were investigated due to the difficulty of finding RHD patients with SR. Although the left atrium plays a key role in the development of AF, only right atrial appendage tissues could be obtained during cardiac surgery. However, a recent study concluded that there are similarities between the right and left atrial appendage, at least in terms of the expression levels of proteins associated with the cytoskeleton, energy metabolism and cardiac cytoprotection (11) . Another limitation was that the biological effects of the identified proteins were not validated in a biological model, since an appropriate mammalian cell model of AF has yet to be developed. Further studies using animal models of AF to explore the biological effects of the identified differently expressed proteins will soon be conducted by our group.
In conclusion, the data presented in this study may enable a better understanding of the molecular mechanisms of AF and may aid in drug development.
